DaVita (MIL:1DVA) Valuation Rank


MIL:1DVA DaVita Inc MIL:1DVA
61 GF Score
Price €207.10
GF Value €148.57
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is DaVita Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

DaVita Valuation Rank Related Terms

MIL:1DVA
61GF Score
DaVita Inc MIL:1DVA
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is DaVita (MIL:1DVA) Overvalued in 2026?

Based on GuruFocus' analysis, DaVita stock appears to be overvalued. The current stock price of €207.10 is trading 39.4% above its estimated GF Value™ of €148.57. GuruFocus considers DaVita to be Significantly Overvalued.

Key valuation signals for MIL:1DVA:

  • Valuation Rank:
  • GF Value™: €148.57 vs. price of €207.10 (39.4% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the MIL:1DVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DaVita Business Description

Address 2000 16th Street, Denver, CO, USA, 80202
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
61GF Score

Get the complete analysis for MIL:1DVA

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€207.10
Price
€148.57
GF Value